Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Shamash

Showing results (31-40 of 110) with videos related to

Pageof 11
Sort By:
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 15, 2020
Pathological predictors of metastatic disease in testicular non-seminomatous germ cell tumors: which tumor-node-metastasis staging system?Glenda Scandura, Thomas Wagner, Luis Beltran, et al.
Urologic Nursing|June 13, 2014
Initial experience of intravesical gemcitabine for patients with high-risk superficial transitional cell carcinoma of the bladder following BCG failurePaula Allchorne, Benjamin W Lamb, Janette Kinsella, et al.
Oncotargets and Therapy|December 4, 2010
The efficacy and safety of irinotecan cisplatin and mitomycin chemotherapy in sunitinib pre-treated metastatic clear cell renal cancerThomas Powles, Siobhan McFaul, Justin Stebbing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2012
Whole blood stem cell reinfusion and escalated dose melphalan in castration-resistant prostate cancer: a phase 1 studyJonathan Shamash, Jimmy Jacob, Samir Agrawal, et al.
BJU International|June 26, 2010
The application of the National Institute of Clinical Excellence guidelines for treatment of metastatic renal cell carcinoma in the United Kingdom: friend or foe?Thomas Powles, Rob Jones, Simon Chowdhury, et al.
Oncology and Therapy|January 19, 2026
Treatment Strategies in Metastatic Castration-Resistant Prostate Cancer: A Narrative Review of Considerations in the Post-ARTA, Post-Docetaxel SettingKenrick Ng, Birth-Lynn Tyers, Aruni Ghose, et al.
Urologia Internationalis|December 25, 2017
A Prospective Audit of Intermittent Anti-Androgen verses Pituitary Blockade Suggests a Bipolar Androgen Type Strategy May Be Safe in Untreated Prostate CancerTimothy Oliver, Peter Wilson, Wendy Ansell, et al.
British Journal of Haematology|April 26, 2017
Intravascular large B-cell lymphoma presenting as a pituitary mass with bilateral adrenal enlargement and haemophagocytic lymphohistiocytosisShazia Hussain, Simon Hallam, Luis Beltran, et al.
BJU International|July 16, 2020
Neutropenic sepsis rates in patients receiving bleomycin, etoposide and cisplatin chemotherapy using olanzapine and reduced doses of dexamethasone compared to a standard antiemetic regimenErnese Gjafa, Kenrick Ng, Tami Grunewald, et al.
Therapeutic Advances in Medical Oncology|September 3, 2025
Treatment de-escalation for metastatic good-risk seminoma with carboplatin AUC10: predictive factors and patterns of relapseNasreen Abdul Aziz, Didjier Danger Masangwi, Sushila Ganguli, et al.
Pageof 11

Showing results (31-40 of 110) with videos related to

Sort By:
Pageof 11
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 15, 2020
Pathological predictors of metastatic disease in testicular non-seminomatous germ cell tumors: which tumor-node-metastasis staging system?Glenda Scandura, Thomas Wagner, Luis Beltran, et al.
Urologic Nursing|June 13, 2014
Initial experience of intravesical gemcitabine for patients with high-risk superficial transitional cell carcinoma of the bladder following BCG failurePaula Allchorne, Benjamin W Lamb, Janette Kinsella, et al.
Oncotargets and Therapy|December 4, 2010
The efficacy and safety of irinotecan cisplatin and mitomycin chemotherapy in sunitinib pre-treated metastatic clear cell renal cancerThomas Powles, Siobhan McFaul, Justin Stebbing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2012
Whole blood stem cell reinfusion and escalated dose melphalan in castration-resistant prostate cancer: a phase 1 studyJonathan Shamash, Jimmy Jacob, Samir Agrawal, et al.
BJU International|June 26, 2010
The application of the National Institute of Clinical Excellence guidelines for treatment of metastatic renal cell carcinoma in the United Kingdom: friend or foe?Thomas Powles, Rob Jones, Simon Chowdhury, et al.
Oncology and Therapy|January 19, 2026
Treatment Strategies in Metastatic Castration-Resistant Prostate Cancer: A Narrative Review of Considerations in the Post-ARTA, Post-Docetaxel SettingKenrick Ng, Birth-Lynn Tyers, Aruni Ghose, et al.
Urologia Internationalis|December 25, 2017
A Prospective Audit of Intermittent Anti-Androgen verses Pituitary Blockade Suggests a Bipolar Androgen Type Strategy May Be Safe in Untreated Prostate CancerTimothy Oliver, Peter Wilson, Wendy Ansell, et al.
British Journal of Haematology|April 26, 2017
Intravascular large B-cell lymphoma presenting as a pituitary mass with bilateral adrenal enlargement and haemophagocytic lymphohistiocytosisShazia Hussain, Simon Hallam, Luis Beltran, et al.
BJU International|July 16, 2020
Neutropenic sepsis rates in patients receiving bleomycin, etoposide and cisplatin chemotherapy using olanzapine and reduced doses of dexamethasone compared to a standard antiemetic regimenErnese Gjafa, Kenrick Ng, Tami Grunewald, et al.
Therapeutic Advances in Medical Oncology|September 3, 2025
Treatment de-escalation for metastatic good-risk seminoma with carboplatin AUC10: predictive factors and patterns of relapseNasreen Abdul Aziz, Didjier Danger Masangwi, Sushila Ganguli, et al.
Pageof 11